Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
1. A method of inhibiting the HGF/c-MET signaling pathway in a cell comprising contacting said cell with a compound of 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
or a pharmaceutically acceptable salt thereof.
2. A method of treating gastric cancer, cancer of the kidney, liver cancer, lung cancer, or glioblastoma in a patient comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein said cancer is gastric cancer.
4. The method of claim 1 , wherein said cancer is cancer of the kidney.
5. The method of claim 1 , wherein said cancer is liver cancer.
6. The method of claim 1 , wherein said cancer is lung cancer.
7. The method of claim 1 , wherein said cancer is glioblastoma.
8. The method of claim 2 , wherein said cancer is gastric cancer.
9. The method of claim 2 , wherein said cancer is cancer of the kidney.
10. The method of claim 2 , wherein said cancer is liver cancer.
11. The method of claim 2 , wherein said cancer is lung cancer.
12. The method of claim 2 , wherein said cancer is glioblastoma.